<?xml version="1.0" encoding="UTF-8"?><xmi:XMI xmlns:cas="http:///uima/cas.ecore" xmlns:xmi="http://www.omg.org/XMI" xmlns:type="http:///org/apache/uima/trials/type.ecore" xmlns:tcas="http:///uima/tcas.ecore" xmi:version="2.0">
    <cas:NULL xmi:id="0"/>
    <tcas:DocumentAnnotation xmi:id="1" sofa="6" begin="0" end="2079" language="x-unspecified"/>
    <type:ORR xmi:id="13" sofa="6" begin="1542" end="1548"/>
    <type:ORR xmi:id="17" sofa="6" begin="1553" end="1559"/>
    <type:OSMean xmi:id="21" sofa="6" begin="1596" end="1607"/>
    <type:OSMean xmi:id="29" sofa="6" begin="1612" end="1623"/>
    <type:PFSMean xmi:id="33" sofa="6" begin="1670" end="1681"/>
    <type:PFSMean xmi:id="37" sofa="6" begin="1686" end="1696"/>
    <cas:Sofa xmi:id="6" sofaNum="1" sofaID="_InitialView" mimeType="text" sofaString="BACKGROUND &amp; OBJECTIVE: Present chemotherapy for hepatocellular carcinoma (HCC)&#13;&#10;is not effective. To improve the effect of chemotherapy, in vitro chemo-drug&#13;&#10;sensitive testing system, adenosine triphosphate tumor chemosensitive assay&#13;&#10;(ATP-TCA) system, was used to evaluate efficacies of chemotherapeutic drugs, and &#13;&#10;to guide clinical individual chemotherapy for HCC patients.&#13;&#10;METHODS: ATP-TCA system was applied to test efficacies of 5-fluorouracil (5-FU), &#13;&#10;mitomycin (MMC), cisplatin (DDP), oxaliplatin (OXA), epirubicin (EPI),&#13;&#10;gemcitabine (GEM), irinotecan (CPT-11), etoposide (VP-16), and paclitaxel (PTX)&#13;&#10;on 50 HCC samples. Twenty-three HCC patients received ATP-TCA-directed&#13;&#10;chemotherapy (ATP-TCA group)รป 20 HCC patients received surgery and routine&#13;&#10;treatments (control group). Clinical outcomes of these patients were observed for&#13;&#10;162 weeks.&#13;&#10;RESULTS: The assessable rate of ATP-TCA result is 90.8%. In the 50 samples, the&#13;&#10;sensitive (moderate to high degree) rates were 46% to PTX, 44% to CPT-11, 36% to &#13;&#10;GEM, 14% to MMC, 12% to EPI, 8% to DDP, 6% to VP-16, 6% to OXA, and 4% to 5-FU,&#13;&#10;respectively. In clinical trial, at the research end-point, no significant&#13;&#10;differences were found in partial remission (PR), complete remission (CR), stable&#13;&#10;disease (SD), and mortality between ATP-TCA group and control group (P &gt; 0.05),&#13;&#10;but progression disease (PD) rate was significantly higher in control group than &#13;&#10;in ATP-TCA group (60.00% vs.13.04%, P=0.003); significant differences were found &#13;&#10;in overall response rate (ORR) (60.86% vs. 30.00%, P =0.043), overall survival&#13;&#10;(OS) (78.91 weeks vs. 27.21 weeks, P=0.006), and progress-free survival (PFS)&#13;&#10;(30.52 weeks vs. 4.78 weeks, P=0.005) between ATP-TCA group and control group.&#13;&#10;CONCLUSIONS: ATP-TCA system might be useful in evaluating the efficacy of&#13;&#10;chemotherapeutic drugs on HCC samples, and in planning individualized&#13;&#10;chemotherapy regimen for HCC patients. PTX, CPT-11 and GEM might be potential&#13;&#10;drugs for the treatment of HCC. ATP-TCA-guided chemotherapy might prolong&#13;&#10;survival time of HCC patients."/>
    <cas:View sofa="6" members="1 13 17 21 29 33 37"/>
</xmi:XMI>
